Supervisor: Indira Nederpelt

Division contact information & address

A next, general pharmacological problem to be tackled is how drug-target binding kinetics in vivo, affects target occupancy as an important indicator of the time-course of drug effects.

In the last decades, activity-based protein profiling (ABPP) has emerged as a powerful chemical tool that may aid the ever-challenging drug discovery process.

Harm reduction in practice: a comparative analysis of the Dutch and Brazilian approach towards drug users.

Discovery of metastasis promoting candidate drug targets

Drug Discovery and Safety consists of 120 European Credit Transfer System (EC) points.

Over several decades, a variety of computational methods for drug discovery have been proposed and applied in practice. With the accumulation of data and the development of machine learning methods, computational drug design methods have gradually shifted to a new paradigm, i.e. deep learning methods…

What are the various forms of inter-organizational collaboration in the public safety sector? How are different forms of inter-organizational collaborative arrangements related? What is the relationship between inter-organizational collaboration and innovation in the public safety sector?

Benjamin Fogarty-Valenzuela published the article 'Pedagogies of Prohibition: Time, Education, and the War on Drugs in Rio de Janeiro’s Zona Norte' in Cultural Anthropology 37. The article’s three sections focus on three forms of temporal control—busyness, punctuality, and rhythm—and each demonstrates…

We are committed to provide you with meaningful, rigorous and quality graduate experiences in a personalized environment with a cutting edge research infrastructure and internationally renowned supervisors.

The Minor Computational Approaches to Disease, Signaling and Drug Targets (CADSDT) is focused on fundamental scientific research required for discovery of new drug targets and development of new drugs.

This thesis focuses on the application of lipid-based nanomedicine in drug delivery, including small molecular antitumor drugs and biomacromolecules including mRNA, and evaluates their biological performance.

Can we develop a generic method for Quan/Qual analysis of small molecule drugs, their metabolites and endogenous metabolites in (pre-)clinical samples?

Although rarely considered by the pharmaceutical industry or clinicians, 24-hour rhythms in physiology are a factor of potential influence on the pharmacokinetics and pharmacodynamics of drugs.

Another research line is the development of a spatial CNS drug distribution model, by ultimately including the 3-dimensional anatomical organization of the CNS.

How can we extend the drug residence time to combat diseases more effectively?

Security and safety challenges rank among the most pressing issues of modern times. Challenges such as cyber-crime, terrorism, and environmental disasters impact the lives of millions across the globe. The course will introduce you to this broad theme in an increasingly complex world.

Currently, more than 80% of drugs are used in an off-label manner in critically ill neonates.

This thesis describes the importance of being able to control the selectivity of potential drug candidates.

During the course of drug discovery translational steps are made.

Source: ChemMedChem (2015)

Heart failure is a major health care problem with high mortality.

Can effective synergists be identified to enhance the effect of antibiotics against Gram negative pathogens?

The Drug Discovery and Safety specialisation consists of compulsory and optional components.

Data analysis with Python and R are rapidly becoming essential skills for modern scientists. Therefore, we are offering courses to develop your scientific computing skills. Those courses are optional for LACDR PhD candidates.

Human and animal cells are very complex: very different chemical processes are going on at the same time, but they are separated from each other because the cells are divided in compartments. These compartments may also have a profound effect on the potential efficacy of therapeutics, because the drug…

The Leiden Academic Centre for Drug Research (LACDR) is responsible for the research and education in Bio-Pharmaceutical Sciences carried out at Leiden University.

The GMP Facility facilitates development and production of Advanced Therapy Medicinal Products (ATMPs) and chemical (peptide) synthesis.

Promotor: A. Kros

The research area of this division is focused on the development of novel therapeutic modalities and novel concepts in early drug discovery, in order to better predict ligand-target interactions.

In this project, we aim to develop mathematical models to mechanistically and quantitatively predict the dynamics of cellular stress pathway activation and its relation with toxic effects when cells are exposed to various toxicants.

Our Division has created and maintains the Visualisation Core Facilities of the LACDR. This is a multi-user facility offering basic and advanced microscopic techniques to scientists of the LACDR.

PhD defence

Activity-based protein profiling (ABPP, also termed chemical proteomics), is one of the pillars of chemical biology, and at LED3 we have taken it to the next level. ABPP allows the assessment of protein function in live cells and tissues, which means that the activity of a complete protein family can…

The research conducted at the Leiden Academic Centre for Drug Research is clustered within the divisions of BioTherapeutics, Drug Discovery & Safety and Systems Biomedicine and Pharmacology, and the Metabolomics and Analytics Centre.

Promotores: Prof.dr. H. S. Overkleeft, Prof.dr. G. A. van der Marel

Research in the BioTherapeutics research programme is aimed at a smoother and speedier transition from preclinical research to pharmacological interventions, and the delivery of drugs in the human body by use of small molecules and biologics.

Clinical development of drugs for central nervous system (CNS) disorders has been particularly challenging and still suffers from high attrition rates.

The need for novel drugs as well as innovations in their development and application is as urgent as ever. Below we present our vision , mission, and our key research areas.

Promotor: A.P. IJzerman Co-promotor: L.H. Heitman

This project’s aim is to critically assess current homicide data sources in order to develop a proposal for long-term EU-level monitoring of DRH.

Safety issues of the transport and storage of Chlorine, ammonia and LPG.

Exploring the mechanism of targeted nanoparticle-mediated drug delivery using the zebrafish model